The Food and Drug Administration has ordered GlaxoSmithKline to stop enrolling people in a controversial clinical trial comparing diabetes drugs, and to notify more than 1,300 people already undergoing tests that they may be at greater risk for heart attacks because they have taken Avandia. The company has said it would comply with the FDA order.
Comments